The twelve US (FDA) approved small molecule protein kinase inhibitors.

Name	Type	Other names	Target(s)	Cancer type
Imatinib	Nonreceptor tyrosine kinase inhibitor	Glivec, Gleevec	a multitargeted c-kit, PDGF-R and c-ABL inhibitor	Newly diagnosed adult patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase; Patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy; Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy; Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (ALL); . Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements; Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown; . Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL); . Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP); Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST); -Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.
Gefitinib	Receptor tyrosine kinase inhibitor	Iressa, ZD-1839	EGFR and Akt inhibitor	Locally advanced or metastatic non-small-cell lung cancer (NSCLC) after failure of platinum-based and docetaxel chemotherapy
Erlotinib	Receptor tyrosine kinase inhibitor	Tarceva, CP-358774, OSI-774, NSC-718781	EGFR inhibitor	Locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen; Maintenance treatment of NSCLC patients whose disease has not progressed after four cycles of platinum-based first-line chemotherapy; In combination with gemcitabine for treatment of patients with locally advanced, unresectable or metastatic pancreatic carcinoma.
Sorafenib	Receptor tyrosine kinase inhibitor	Nexavar	VEGFR, PDGFR and RAF/MEK/ERK cascade inhibitor	Unresectable hepatocellular carcinoma (HCC); Advanced renal cell carcinoma (RCC)
Dasatinib	Nonreceptor tyrosine kinase inhibitor	Sprycel, BMS-354825, BMS354825	ATP-competitive, dual SRC/ABL inhibitor. It inhibits all members of the Src family, including c-Src, Lck, Fyn, and Yes	Chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (CP-CML); Chronic phase (CP) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy; Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.
Sunitinib	Receptor tyrosine kinase inhibitor	Sutent	multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase inhibitor	Advanced renal cell carcinoma; Gastrointestinal stromal tumor (GIST) after disease progression on, or intolerance to, imatinib mesylate
Nilotinib	Nonreceptor tyrosine kinase inhibitor	Tasigna, AMN-107	Inhibitor of BCR-ABL	Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP-CML); Chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib.
Lapatinib	Receptor tyrosine kinase inhibitor	Tykerb	EGFR and HER2 inhibitor	Hormone-receptor- and HER2-positive advanced breast cancer; HER2-overexpressing breast cancer
Pazopanib	Receptor tyrosine kinase inhibitor	Votrient	VEGFR-1, -2, and -3 inhibitor	Advanced renal cell carcinoma
Vandetanib	Receptor tyrosine kinase inhibitor	Zactima	VEGFR and EGFR inhibitor	Unresectable, locally advanced, or metastatic medullary thyroid cancer
Vemurafenib	Serine/threonine kinase inhibitor	Zelboraf, PLX-4032, RG7204, R7204 & RO5185426	BRAf inhibitor	Unresectable or metastatic melanoma carrying the mutant BRAFV600E.
Crizotinib	Serine/threonine kinase inhibitor	Xalkori, PF-2341066	ALK and HGFR inhibitor	Locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an approved FDA-approved test.